Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial
У вашего броузера проблема в совместимости с HTML5
Prof Ribas presents the findings of a phase III trial, which showed pembrolizumab to be preferable to ipilimumab in advanced melanoma, at a press conference at AACR 2015.